Business
Contract with Genting TauRx Diagnostic Centre
Contract with Genting TauRx Diagnostic Centre.
About this update from Proteome Sciences Plc
[{"type":"text","content":"\n \nRNS Number : 5975S Proteome Sciences PLC 25 September 2014 \n \n\n \n \n \n \nProteome Sciences plc\n \nProteome Sciences signs $2m contract with Genting TauRx Diagnostic Centre to develop diagnostic panels to detect Alzheimer's disease and monitor treatment efficacy\nLondon, September 25th 2014. Proteome Sciences plc (\"Proteome Sciences\") is pleased to announce that its PS Biomarker Services Division (\"PS\") has been selected to develop diagnostic products for Genting TauRx Diagnostic Centre Sdn. Bhd. (\"GTD\"), an affiliate of TauRx Therapeutics Ltd (\"TauRx Therapeutics\"). The project will involve PS analysing blood samples from patients enrolled in a phase 3 trial of the experimental Alzheimer's drug LMTX, targeting the tau pathway, and from age-matched controls. LMTX is being developed by TauRx Therapeutics for the treatment for Alzheimer's disease of mild to moderate severity.\nKey to selecting Proteome Sciences was its established portfolio of blood biomarkers for predicting the progression of patients with Mild Cognitive Impairment and Alzheimer's disease along with its proprietary TMT-MS3 plasma proteomics workflows. The study will involve blood proteomic profiling of approximately 1,000 individuals and construction of targeted protein panels for detection of Alzheimer's disease and for monitoring of treatment efficacy.\nUnder the terms of the agreement, Proteome Sciences will receive research fees totalling $2M comprising upfront and milestone payments. GTD will receive a license to Proteome Sciences' existing blood biomarkers for AD and both parties will share commercialisation rights of the diagnostic assays developed.\nCommenting on the Agreement, Dr. Ian Pike, Chief Operating Officer of Proteome Sciences said:\n\"We are delighted that GTD has chosen PS Biomarker Services to develop diagnostic assays in the challenging field of Alzheimer's disease. Having tests that can reliably detect the disease, select the right patients to receive LMTX and monitor their response will be critical in ensuring more people can benefit from this potentially ground-breaking treatment.\"\n\"Our proprietary proteomics services using Tandem Mass Tags and MS3 quantification along with our long and successful track record in discovering and developing Alzheimer's disease biomarkers was a ...